* TRxADE Health Inc MEDS.OQ MEDS.O is expected to show a
fall
in quarterly revenue when it reports results on August 14.
* The Lutz Florida-based company is expected to report a
33.5% decrease in revenue to $2.18 million from $3.28 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for TRxADE Health Inc
is for
a loss of 75 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for TRxADE
Health Inc
is $12.75, above its last closing price of $8.16.
This summary was machine generated August 12 at 02:01 GMT. All
figures in US dollars unless otherwise stated